Short Interest in Astria Therapeutics, Inc. (NASDAQ:ATXS) Declines By 5.7%

Astria Therapeutics, Inc. (NASDAQ:ATXS) saw a significant decrease in short interest in the month of July. As of July 15th, there was short interest totalling 4,000,000 shares, a decrease of 5.7% from the June 30th total of 4,240,000 shares. Based on an average daily trading volume, of 570,400 shares, the days-to-cover ratio is presently 7.0 days. Currently, 9.2% of the shares of the stock are short sold.

Institutional Investors Weigh In On Astria Therapeutics

A number of large investors have recently added to or reduced their stakes in the company. Panagora Asset Management Inc. grew its holdings in Astria Therapeutics by 104.7% during the 2nd quarter. Panagora Asset Management Inc. now owns 30,926 shares of the biotechnology company’s stock valued at $281,000 after purchasing an additional 15,816 shares in the last quarter. Bank of New York Mellon Corp grew its holdings in Astria Therapeutics by 6.9% during the 2nd quarter. Bank of New York Mellon Corp now owns 139,071 shares of the biotechnology company’s stock valued at $1,266,000 after purchasing an additional 8,965 shares in the last quarter. Virtu Financial LLC acquired a new stake in Astria Therapeutics during the 1st quarter valued at $427,000. RA Capital Management L.P. acquired a new position in Astria Therapeutics during the 1st quarter worth $62,115,000. Finally, Artal Group S.A. acquired a new position in Astria Therapeutics during the 1st quarter worth $12,445,000. 98.98% of the stock is owned by institutional investors and hedge funds.

Astria Therapeutics Stock Down 1.6 %

NASDAQ:ATXS opened at $11.43 on Wednesday. Astria Therapeutics has a fifty-two week low of $4.26 and a fifty-two week high of $16.90. The firm’s 50 day moving average is $9.82 and its two-hundred day moving average is $11.25.

Astria Therapeutics (NASDAQ:ATXS) last released its quarterly earnings data on Thursday, May 9th. The biotechnology company reported ($0.38) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.03). On average, analysts forecast that Astria Therapeutics will post -1.56 EPS for the current year.

Wall Street Analyst Weigh In

Several analysts have recently commented on the stock. TD Cowen assumed coverage on shares of Astria Therapeutics in a research report on Monday. They issued a “buy” rating and a $35.00 price target on the stock. Oppenheimer lowered their price target on shares of Astria Therapeutics from $29.00 to $25.00 and set an “outperform” rating on the stock in a research report on Tuesday, May 21st. Wedbush reiterated an “outperform” rating and issued a $22.00 price target on shares of Astria Therapeutics in a research report on Friday, May 10th. Finally, HC Wainwright reiterated a “buy” rating and issued a $16.00 price target on shares of Astria Therapeutics in a research report on Friday, May 10th. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat, Astria Therapeutics currently has a consensus rating of “Buy” and an average target price of $25.00.

About Astria Therapeutics

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.